Product Information
MYRBETRIQ ER 8 MG/ML SUSP is a brand product labeled by Astellas Pharma US, Inc., priced at $2.2070 per ML under NDC 00469502099. Its NADAC has been published 168 times since Jul 19, 2023.
FDA first approved this application on Mar 25, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
8 mg/mL
Manufacturer
Astellas Pharma US, Inc.NDC
00469502099
Classification
Brand
Dosage Form
GRANULE, FOR SUSPENSION, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MIRABEGRONApproval Type
New Drug (NDA)
FDA Application
NDA213801FDA Approved
3/25/2021
TE Code
AB
On Market Since
3/25/2021
Pharmacological Classes
Price Statistics
The NADAC for MYRBETRIQ ER 8 MG/ML SUSP has been published 168 times since Jul 19, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.2070 per ML |
|---|---|
| All-time high | $2.2171 (Apr 10, 2024) |
| All-time low | $2.2068 (Jul 22, 2026) |
| 52-week high | $2.2135 |
| 52-week low | $2.2068 |
| Median price | $2.2131 |
| Average price | $2.2128 |
| Largest weekly change | -0.4% (Apr 17, 2024) |
| Weeks tracked | 168 |
| Tracking since | Jul 19, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the mirabegron market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Astellas Pharma US, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
mirabegron market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta3-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MYRBETRIQ ER 8 MG/ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for MYRBETRIQ ER 8 MG/ML SUSP, manufactured by Astellas Pharma US, Inc., is $2.2070 per ML (NDC 00469502099), effective Sep 30, 2026.
How has the price of MYRBETRIQ ER 8 MG/ML SUSP changed over time?
Over the history we have for it, the NADAC for MYRBETRIQ ER 8 MG/ML SUSP has held within roughly two percent of its current level. It has been tracked across 168 weekly CMS publications since Jul 19, 2023.
What are the highest and lowest recorded NADAC prices for MYRBETRIQ ER 8 MG/ML SUSP?
Since Jul 19, 2023, the NADAC for MYRBETRIQ ER 8 MG/ML SUSP has ranged from a low of $2.2068 (Jul 22, 2026) to a high of $2.2171 (Apr 10, 2024), with a median of $2.2131 per ML.
Are there cheaper alternatives to MYRBETRIQ ER 8 MG/ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of MYRBETRIQ ER 8 MG/ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MYRBETRIQ ER 8 MG/ML SUSP?
MYRBETRIQ ER 8 MG/ML SUSP (NDC 00469502099) is labeled by Astellas Pharma US, Inc., and CMS classifies it as a brand product.